Single-Chain Multivalent Binding Proteins with Effector Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies face challenges such as large size hindering tissue penetration, rapid clearance, lack of effector functions, and toxicity issues, limiting their effectiveness in treating diseases like cancer and autoimmune disorders.
Innovation Solution
Development of multivalent single-chain binding proteins with effector functions, comprising specific binding domains linked by a constant sub-region and a scorpion linker, allowing for localized effector functions and improved targeting capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used for therapy, then effector functions are provided, but large size hinders tissue penetration
Solution Approach 1:
The antibody molecule is divided into separate functional domains: variable regions for antigen binding and constant regions for effector functions. These segments are recombined into a single-chain format that separates the large Fc region from the binding regions, allowing the binding domains to penetrate tissue while the constant domain provides effector functions when engaged with immune cells
Solution Approach 2:
The patent transitions from traditional two-chain antibody structure to a single-chain architecture, fundamentally changing the dimensional organization of antibody domains. This reconfiguration allows the molecule to maintain effector functions while reducing the effective size and complexity that hinder tissue penetration
2Measurement precision
If conventional antibodies are used for therapy, then targeting capability is provided, but rapid clearance limits therapeutic duration
Solution Approach 1:
The patent modifies the physical and chemical parameters of the antibody molecule by creating a single-chain format with altered molecular weight, shape, and hydrodynamic properties. These parameter changes affect pharmacokinetics, potentially extending circulation half-life while preserving antigen binding affinity and specificity
3Reliability
If conventional antibodies are used for therapy, then effector functions are provided, but toxicity issues limit effectiveness
Solution Approach 1:
The patent concentrates effector functions into a localized constant domain rather than distributing them throughout a large molecular structure. This localization allows precise engagement with immune effector cells only at the target site, reducing off-target toxicity while maintaining therapeutic efficacy through focused immune activation
4Length of moving object
If multivalent single-chain binding proteins are developed, then tissue penetration is improved, but device complexity increases
Solution Approach 1:
The patent merges multiple antibody domains into a single continuous polypeptide chain, combining variable regions from different antibodies with constant regions in a unified structure. This consolidation simplifies the overall architecture compared to multi-chain complexes while maintaining multivalency and effector functions through strategic domain arrangement
Data Source
AI summary
Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.